Rapid Developability Assessments to Formulate Recombinant Protein Antigens as Stable, Low-Cost, Multi-Dose Vaccine Candidates: Case-Study With Non-Replicating Rotavirus (NRRV) Vaccine Antigens.
Journal Information
Full Title: J Pharm Sci
Abbreviation: J Pharm Sci
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Funding Disclosure
Evidence found in paper:
"The authors would like to thank Bill & Melinda Gates Foundation for providing the financial support for this work (Investment ID OPP1154682). This study was also supported in part by the Koch Institute Support (core) grant P30-CA14051 from the National Cancer Institute. We thank Laura Crowell from the Love lab for comments on the manuscript. The authors wish to acknowledge Drs. Stan Cryz and Bob Sitrin at PATH for providing E. coli cell paste of the NRRV antigens, antibody reagents, ELISA protocols for the competitive ELISA assays, and for helpful and informative discussions."
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025